Contact this trialFirst, we need to learn more about you.
SGLT2 Inhibitor
Intranasal Insulin + Empagliflozin for Alzheimer's Disease
Recruiting0 awardsPhase 2
Winston-Salem, North Carolina
This trial will study the effects of intranasal insulin and the diabetes drug empagliflozin on people with early Alzheimer's disease or mild cognitive impairment.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service